Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib Therapy

Diane Tseng; Xenos L Mason; Tomas G Neilan; Ryan J Sullivan

doi:10.1634/theoncologist.2016-0080

Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib Therapy

Oncologist. 2016 Sep;21(9):1136-7. doi: 10.1634/theoncologist.2016-0080. Epub 2016 Jul 7.

Authors

Diane Tseng¹, Xenos L Mason², Tomas G Neilan³, Ryan J Sullivan²

Affiliations

¹ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard University, Cambridge, Massachusetts, USA.
² Harvard University, Cambridge, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
³ Harvard University, Cambridge, Massachusetts, USA; Department of Medicine, Department of Cardiology, Cardio-Oncology Program, Massachusetts General Hospital, Boston, Massachusetts, USA.

Abstract

Life-threatening heart failure can occur with trametinib therapy and is reversible. This article provides recommendations for evaluation of patients receiving trametinib, including those who develop severe cardiomyopathy.

MeSH terms

Humans
Melanoma / complications
Melanoma / drug therapy*
Melanoma / pathology
Pyridones / adverse effects*
Pyridones / therapeutic use
Pyrimidinones / adverse effects*
Pyrimidinones / therapeutic use
Respiratory Insufficiency / chemically induced
Respiratory Insufficiency / physiopathology*
Shock, Cardiogenic / chemically induced
Shock, Cardiogenic / physiopathology*

Substances

Pyridones
Pyrimidinones
trametinib